CATIE-News

CATIE’s bite-sized HIV and hepatitis C news bulletins.

Lemon myrtle oil tested against mollusca

28 June 2004

Scientists are developing an interest in studying the essential oils from the following plants because of their ability to impair the growth of microbes:

- lemon
- lemon verbena
- lemongrass
- lemon myrtle

Laboratory studies have found that lemon myrtle oil impairs the growth of bacteria and fungi and may be stronger than tea-tree oil in this regard. Australian researchers are planning to conduct test-tube experiments to assess lemon myrtle oil’s antiviral activity.

Study details and results

Despite the lack of published work on lemon myrtle’s antiviral properties, researchers in Idaho have reported that essential oil of the herb lemon myrtle has been tested in a placebo-controlled study of molluscum contagiosum virus (MCV) infection in HIV negative children. Using a 10% solution of lemon myrtle oil, researchers found that it reduced the number of MCV skin lesions by 90% in nine of 16 children who used it. Among the 15 children who received placebo, there was no significant reduction in MCV lesions. In 12 of these placebo recipients, mollusca lesions either stayed the same or became worse. The remaining three children were withdrawn from the study by their parents because their mollusca became worse.

The results from this study are promising and need to be confirmed in another clinical trial. Also, the safety and effectiveness of lemon myrtle oil in PHAs with mollusca or other skin conditions will not be known until further studies are done.

—Sean R. Hosein

REFERENCES


Disclaimer

Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV- and hepatitis C-related illness and the treatments in question.

CATIE provides information resources to help people living with HIV and/or hepatitis C who wish to manage their own health care in partnership with their care providers. Information accessed through or published or provided by CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments and we urge users to consult as broad a range of sources as possible. We strongly urge users to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature.

CATIE endeavours to provide the most up-to-date and accurate information at the time of publication. However, information changes and users are encouraged to ensure they have the most current information. Users relying solely on this information do so entirely at their own risk. Neither CATIE nor any of its partners or funders, nor any of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from the use or misuse of any such information. Any opinions expressed herein or in any article or publication accessed or published or provided by CATIE may not reflect the policies or opinions of CATIE or any partners or funders.

Information on safer drug use is presented as a public health service to help people make healthier choices to reduce the spread of HIV, viral hepatitis and other infections. It is not intended to encourage or promote the use or possession of illegal drugs.

Permission to Reproduce

This document is copyrighted. It may be reprinted and distributed in its entirety for non-commercial purposes without prior permission, but permission must be obtained to edit its content. The following credit must appear on any reprint: This information was provided by CATIE (the Canadian AIDS Treatment Information Exchange). For more information, contact CATIE at 1.800.263.1638.

© CATIE

Production of this content has been made possible through a financial contribution from the Public Health Agency of Canada.

Available online at: